Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have been assigned an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $7.40.

Several equities analysts have recently commented on the company. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday.

Actinium Pharmaceuticals Stock Performance

ATNM stock opened at $1.29 on Friday. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $10.24. The firm has a market cap of $40.24 million, a PE ratio of -0.93 and a beta of -0.27. The firm’s 50 day moving average price is $1.27 and its 200-day moving average price is $1.44.

Institutional Trading of Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp grew its holdings in shares of Actinium Pharmaceuticals by 4.9% in the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock valued at $317,000 after purchasing an additional 11,812 shares in the last quarter. Geode Capital Management LLC boosted its position in Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after buying an additional 19,843 shares during the period. Vontobel Holding Ltd. acquired a new position in shares of Actinium Pharmaceuticals in the fourth quarter worth $32,000. Creative Financial Designs Inc. ADV increased its position in shares of Actinium Pharmaceuticals by 42.7% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock worth $115,000 after acquiring an additional 27,222 shares during the period. Finally, Barclays PLC raised its stake in shares of Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after acquiring an additional 32,784 shares in the last quarter. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).